Recommendations for measuring HIV reservoir size in cure-directed clinical trials
M Abdel-Mohsen, D Richman, RF Siliciano… - Nature medicine, 2020 - nature.com
Nature medicine, 2020•nature.com
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will
require a consensus on how best to measure the numbers of persistently infected cells with
the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the
results of cure-directed strategies in vivo. Current measurements assess various aspects of
the HIV provirus and its functionality and produce divergent results. Here, we provide …
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will
require a consensus on how best to measure the numbers of persistently infected cells with
the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the
results of cure-directed strategies in vivo. Current measurements assess various aspects of
the HIV provirus and its functionality and produce divergent results. Here, we provide …
Abstract
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.
nature.com